TSE:VMD

Viemed Healthcare Competitors

C$11.84
+0.11 (+0.94 %)
(As of 04/22/2021 12:06 PM ET)
Add
Compare
Today's Range
C$11.59
Now: C$11.84
C$11.98
50-Day Range
C$11.42
MA: C$12.32
C$13.13
52-Week Range
C$8.60
Now: C$11.84
C$16.19
Volume23,871 shs
Average Volume173,281 shs
Market CapitalizationC$468.41 million
P/E Ratio12.13
Dividend YieldN/A
BetaN/A

Competitors

Viemed Healthcare (TSE:VMD) Vs. AND, TRIL, CXR, WELL, SIA, and OGI

Should you be buying VMD stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Viemed Healthcare, including Andlauer Healthcare Group (AND), Trillium Therapeutics (TRIL), Concordia International (CXR), WELL Health Technologies (WELL), Sienna Senior Living (SIA), and OrganiGram (OGI).

Andlauer Healthcare Group (TSE:AND) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Andlauer Healthcare Group and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Andlauer Healthcare GroupN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Andlauer Healthcare Group and Viemed Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Andlauer Healthcare Group01102.50
Viemed Healthcare01002.00

Andlauer Healthcare Group currently has a consensus price target of C$43.75, suggesting a potential upside of 21.02%. Given Andlauer Healthcare Group's stronger consensus rating and higher possible upside, analysts plainly believe Andlauer Healthcare Group is more favorable than Viemed Healthcare.

Valuation & Earnings

This table compares Andlauer Healthcare Group and Viemed Healthcare's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Andlauer Healthcare GroupC$314.34 million4.43C$37.59 millionC$0.9837.04
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Viemed Healthcare has lower revenue, but higher earnings than Andlauer Healthcare Group. Viemed Healthcare is trading at a lower price-to-earnings ratio than Andlauer Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Summary

Andlauer Healthcare Group beats Viemed Healthcare on 7 of the 8 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Trillium Therapeutics and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Trillium Therapeutics and Viemed Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Viemed Healthcare01002.00

Trillium Therapeutics currently has a consensus price target of C$25.00, suggesting a potential upside of 109.56%. Given Trillium Therapeutics' higher possible upside, analysts plainly believe Trillium Therapeutics is more favorable than Viemed Healthcare.

Valuation & Earnings

This table compares Trillium Therapeutics and Viemed Healthcare's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,200.87C$-90,462,974.00C($0.88)-13.42
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Viemed Healthcare has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Viemed Healthcare beats Trillium Therapeutics on 4 of the 6 factors compared between the two stocks.

Concordia International (TSE:CXR) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Concordia International and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Concordia International and Viemed Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
Viemed Healthcare01002.00

Valuation & Earnings

This table compares Concordia International and Viemed Healthcare's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Concordia International has higher revenue and earnings than Viemed Healthcare. Concordia International is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Viemed Healthcare on 3 of the 4 factors compared between the two stocks.

WELL Health Technologies (TSE:WELL) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares WELL Health Technologies and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WELL Health TechnologiesN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for WELL Health Technologies and Viemed Healthcare, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WELL Health Technologies01313.00
Viemed Healthcare01002.00

WELL Health Technologies currently has a consensus price target of C$11.56, suggesting a potential upside of 63.72%. Given WELL Health Technologies' stronger consensus rating and higher possible upside, analysts plainly believe WELL Health Technologies is more favorable than Viemed Healthcare.

Valuation & Earnings

This table compares WELL Health Technologies and Viemed Healthcare's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WELL Health TechnologiesC$50.24 million22.91C$-4,912,680.00C($0.03)-234.33
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Viemed Healthcare has higher revenue and earnings than WELL Health Technologies. WELL Health Technologies is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

WELL Health Technologies beats Viemed Healthcare on 5 of the 9 factors compared between the two stocks.

Sienna Senior Living (TSE:SIA) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Sienna Senior Living and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sienna Senior LivingN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Sienna Senior Living and Viemed Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sienna Senior Living02502.71
Viemed Healthcare01002.00

Sienna Senior Living currently has a consensus price target of C$14.65, suggesting a potential upside of 0.69%. Given Sienna Senior Living's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sienna Senior Living is more favorable than Viemed Healthcare.

Earnings and Valuation

This table compares Sienna Senior Living and Viemed Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sienna Senior LivingC$664.23 million1.47C$-24,469,235.00C($0.37)-39.86
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Viemed Healthcare has lower revenue, but higher earnings than Sienna Senior Living. Sienna Senior Living is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

OrganiGram (TSE:OGI) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares OrganiGram and Viemed Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGramC$72.40 million13.22C$-340,283,853.00C($1.14)-2.81
Viemed HealthcareC$131.31 million3.57C$38.61 millionC$0.9812.13

Viemed Healthcare has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for OrganiGram and Viemed Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram42201.75
Viemed Healthcare01002.00

OrganiGram currently has a consensus price target of C$3.77, suggesting a potential upside of 17.75%. Given OrganiGram's higher possible upside, equities research analysts plainly believe OrganiGram is more favorable than Viemed Healthcare.

Profitability

This table compares OrganiGram and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGramN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Summary

Viemed Healthcare beats OrganiGram on 5 of the 8 factors compared between the two stocks.


Viemed Healthcare Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Andlauer Healthcare Group logo
AND
Andlauer Healthcare Group
1.0$36.30+0.4%C$1.39 billionC$314.34 million37.04
TRIL
Trillium Therapeutics
0.9$11.78+2.5%C$1.24 billionC$148,000.00-13.42News Coverage
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
WELL Health Technologies logo
WELL
WELL Health Technologies
0.9$7.03+0.9%C$1.16 billionC$50.24 million-234.33
Sienna Senior Living logo
SIA
Sienna Senior Living
1.3$14.55+0.1%C$976.76 millionC$664.23 million-39.86Dividend Announcement
OrganiGram logo
OGI
OrganiGram
1.2$3.21+0.9%C$948.38 millionC$72.40 million-2.81
HEXO logo
HEXO
HEXO
0.7$7.01+1.7%C$872.61 millionC$111.62 million-3.47
Extendicare logo
EXE
Extendicare
1.2$7.61+0.4%C$683.86 millionC$1.16 billion12.70Dividend Announcement
Knight Therapeutics logo
GUD
Knight Therapeutics
1.7$5.23+0.2%C$674.72 millionC$199.52 million16.39
HLS Therapeutics logo
HLS
HLS Therapeutics
1.4$18.85+1.1%C$606.53 millionC$56.11 million-31.05
BU
Burcon NutraScience
1.2$5.13+0.8%C$553.71 millionC$12,045.005,130.00
APS
Aptose Biosciences
1.3$6.32+4.0%C$539.53 millionN/A-7.49
BLU
BELLUS Health
0.5$5.49+3.1%C$443.39 millionC$15,000.00-8.16
Theratechnologies logo
TH
Theratechnologies
0.7$4.48+0.0%C$423.81 millionC$65.76 million-11.79
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$34.46+2.1%C$392.37 millionC$76.09 million-56.21News Coverage
Gap Up
CRH Medical logo
CRH
CRH Medical
0.7$4.99+0.4%C$355.95 millionC$106.17 million-11.66
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
RIV
RIV Capital
0.8$2.07+1.4%C$285.50 millionC$15.44 million-2.73
FIRE
The Supreme Cannabis
1.0$0.38+0.0%C$275.51 millionC$49.44 million-1.79
AKU
Akumin
0.9$3.85+1.8%C$271.32 millionC$246.08 million-10.58
NEPT
Neptune Wellness Solutions
1.2$1.63+3.1%C$261.48 millionC$52.78 million-1.21
MDNA
Medicenna Therapeutics
0.5$4.87+1.0%C$255.52 millionN/A-15.76
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.51+0.6%C$236.31 millionC$3,000.00-6.07
ICC
ICC Labs
0.5$1.62+6.2%C$228.24 millionC$533,684.0095.29Gap Down
Medical Facilities logo
DR
Medical Facilities
1.6$7.29+0.5%C$228.01 millionC$363.85 million20.83
FRX
Fennec Pharmaceuticals
0.5$8.61+8.8%C$223.89 millionC$170,000.00-9.01Gap Down
TMD
Titan Medical
0.8$2.01+1.5%C$216.86 millionC$20 million-4.45Analyst Report
News Coverage
Gap Up
IVQ
Invesque
0.6$3.85+0.8%C$216.80 millionC$207.96 million-0.93
RVX
Resverlogix
0.7$0.93+2.2%C$212.93 millionN/A66.43Upcoming Earnings
News Coverage
ONC
Oncolytics Biotech
1.2$3.84+1.8%C$198.94 millionN/A-6.86
ATE
Antibe Therapeutics
1.3$4.40+0.9%C$198.41 millionC$9.33 million-5.59Gap Down
Hamilton Thorne logo
HTL
Hamilton Thorne
1.2$1.81+3.9%C$165.83 millionC$39.78 million201.11
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.33+3.8%C$157.78 millionC$10,000.00-3.21
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
0.8$0.30+0.0%C$155.52 millionC$21.50 million-0.60
EPI
ESSA Pharma
0.6$8.20+6.7%C$145.78 millionN/A-8.27
EDT
Spectral Medical
0.5$0.53+3.8%C$133.88 millionC$2.10 million-13.59
IPA
ImmunoPrecise Antibodies
0.4$12.64+3.2%C$123.03 millionC$17.18 million-59.07
HBP
Helix BioPharma
0.5$0.85+3.5%C$119.96 millionN/A-15.45Gap Up
LABS
MediPharm Labs
1.4$0.46+1.1%C$119.95 millionC$36.01 million-0.96
KSI
kneat.com
1.0$2.95+1.7%C$109.53 millionC$7.42 million-34.30
Trilogy International Partners logo
TRL
Trilogy International Partners
1.3$1.68+1.2%C$98.15 millionC$610.30 million-1.62
WMD
WeedMD
1.3$0.31+0.0%C$95.35 millionC$27.21 million-3.47
Protech Home Medical logo
PTQ
Protech Home Medical
1.2$2.14+0.5%C$94.56 millionC$82.22 million-44.58
NINE
Delta 9 Cannabis
1.1$1.03+2.9%C$89.36 millionC$12.87 million19.07Gap Down
ACST
Acasti Pharma
0.8$0.59+5.1%C$88.79 millionC$81,000.0017.35Gap Down
LXG
LexaGene
0.5$0.73+2.7%C$83.27 millionN/A-6.13Gap Down
CENTRIC HEALTH logo
CHH
CENTRIC HEALTH
0.6N/AN/AC$82.18 millionC$125.52 million-2.88Gap Up
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05+20.0%C$76.88 millionC$1.09 million-1.32Gap Up
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.